For patients with NYHA class II–III obstructive HCM,

The Mechanism of Action of CAMZYOS®

CAMZYOS is the first and only approved cardiac myosin inhibitor that targets HCM at the source1,2

The source: dysfunction in the cardiac sarcomere3

An excess of myosin-actin cross-bridges leads to structural changes in the left ventricle.4,5

  • The contractility and energy consumption of the heart are increased
  • The heart’s ability to relax is impaired
  • Ultimately, the left ventricular wall thickens, resulting in a blockage or reduced blood flow

CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin that helps to modulate the number of myosin heads in the off state. This reduces the number of myosin-actin cross-bridges that form.2

CAMZYOS® (mavacamten) Mechanism of Action Graphic

Decreasing the number of excess myosin-actin cross-bridges:

Contracting Heart

Reduced cardiac
contractility2,5

Downward Arrow

Reduced dynamic
LVOT obstruction2

Heart

Improved cardiac
filling pressures2

Energy

Improved energy
consumption1,2

HCM=hypertrophic cardiomyopathy; LVOT=left ventricular outflow tract; NYHA=New York Heart Association.

Patients should have access to a treatment designed to do more than impact symptoms—a treatment that also targets myosin at the source1,2

References:

  1. Olivotto I, Oręziak A, Barriales-Villa R, et al. EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769.
  2. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
  3. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e1311.
  4. Stanford Health Care. Hypertrophic cardiomyopathy. Accessed October 15, 2024. https://stanfordhealthcare.org/medicalconditions/blood-heart-circulation/hypertrophic-cardiomyopathy.html
  5. Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci U S A. 2018;115(35): E8143-E8152.


© 2025 MyoKardia, Inc., a Bristol Myers Squibb company. 
CAMZYOS® and the CAMZYOS and MyCAMZYOS Logos are trademarks of MyoKardia, Inc.

3500-US-2400621   04/25

This site is intended for U.S. Healthcare Professionals only.